Zotepine: Treatment of Schizophrenic Patients Presenting with Predominantly Negative Symptoms - A Double-Blind Study vs Haloperidol;Zotepin: Die Behandlung schizophrener Patienten mit vorherrschender Negativsymptomatik. Eine Doppelblindstudie vs. Haloperidol

Fortschritte der Neurologie Psychiatrie

Volumn 59, Issue , 1991, Pages 36-40

  Barnas, C ^a   Stuppack C H ^a   Miller, C ^a   Haring, C ^a   Sperner Unterweger, B ^a   Fleischhacker, W W ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; ZOTEPINE;

ADULT; CLINICAL ARTICLE; CONFERENCE PAPER; DOUBLE BLIND PROCEDURE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; COMPARATIVE STUDY; DIBENZOTHIEPINS; DOUBLE-BLIND METHOD; DYSKINESIA, DRUG-INDUCED; ENGLISH ABSTRACT; FEMALE; HALOPERIDOL; HUMAN; MALE; MIDDLE AGE; NEUROLOGIC EXAMINATION; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0025866937     PISSN: 07204299     EISSN: 14393522     Source Type: Journal    
DOI: 10.1055/s-2007-1000733     Document Type: Article

References (27)

1. Angrist, B., J. Rotrosen, S. Gershon: Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia. Psychopharmacology 72 (1980) 17-19.
2. Overall, J. D., R. Gorham: Brief Psychiatric Rating Scale (BPRS). In: Collegium Internationale Psychiatriae Scalarum (ed.) : Internationale Skalen fúr Psychiatrie. Beltz Test GmbH, Weinheim 1981.
3. Csernansky, J. G., K. Brown, L. E. Hollister: Is there drug treatment for negative schizophrenic symptoms? Hasp. Formul. 21 (1986) 790-792.
4. Keith, S. J., S. Starr, S. M. Matthews: A team approach to pharmacologic treatment of chronic schizophrenia. Hosp. Community Psy-chiat. 35 (1984) 802-805.
5. Kane, J. M., A. Rifkin, M. Woerner, G. Reardon: Low dose neuroleptics in outpatient schizophrenics. Psychopharmacol. Bull. 18 (1982) 20-21.
6. Cesaree, Z., A. K. Nymann: Differential response to amphetamine in schizophrenia. Acta psychiat. scand. 71 (1985) 523-538.
7. Mackay, A. V.: New antipsychotic agents and the future. J. Clin. Psychiat. 46 (1985) 51-53.
8. Kolivakis, T., H. Azian, E. Kingstone: A double blind comparison of pimozide and chlorpromazine in the maintenance of chronic schizophrenic patients. Curr. ther. Res. 16 (1974) 998-1004.
9. Haas, S., H. Beckmann: Pimozide versus haloperidol in acute schizophrenia. A double blind controlled study. Pharmacopsychiatry 15 (1982) 70-74.
10. Frangos, H., N. P. Zissis, I. Leontopoulos et al.: Double-blind therapeutic evaluation of fluspirilene with fluphenazine decanoate in chronic schizopzhrenics. Acta psychiat. scand. 57 (1978) 436-446.
11. Lapierre, Y. D.: A controlled study of penfluridol in the treatment of chronic schizophrenia. Amer. J. Psychiat. 135 (1978) 956-959.
12. Uchida, S., F. Honda, M. Otsuka et al.: Pharmacological study of [2-chloro-l l- (2-dimethyl-aminoethoxy) dibenzo [b,f] thiepine] (zo-tepine), a new neuroleptic drug. Arzneimittel-Forsch./Drug Res. 29 (1979) 1588-1594.
13. Shimomura, K., H. Satoh, O. Hirai et al.: The central antiserotonin activity of zotepine, a new neuroleptic, in rats. Jap. J. Pharmacol. 32 (1982) 405-412.
14. Uchitomi, Y., S. Yamawaki: Effects of zotepine on serotonin (5-HTi, 5-HT2) receptor function. Jap. J. Neuropsychopharmacol. 8 (1986) 315-322.
15. Noda, K., A. Suzuki, M. Okui, H. Noguchi, M. Nishiura, N. Nishiura: Pharmacokinetics and metabolism of 2-chloro-l l- (2-dimethylami-nomethoxy) -dibenzo[b,f]thiepine (zotepine) in rat, mouse, dog and man. Arzneimittel-Forsch./Drug Res. 29 (1979) 1595-1600.
16. Amamoto, H., T. Goto: Clinical use of zotepine. Clin. Rep. 14 (1980) 1660-1682.
17. Arikawa, K., I. Yamauchi, H. Mukasa, A. Ishibashi, M. Matsuoka, T. Miura: Clinical experience with zotepine in schizophrenia. Jap. J. Clin. Psychiat. 9 (1980) 653-666.
18. Fleischhacker, W. W., C. Barnas, C. H. Stuppäck, B. Unterweger, C. Miller, H. Hinterhuber: Zotepine vs. haloperidol in paranoid schizophrenia: a double blind trial. Psychopharmacol. Bull. 25 (1989) 97-100.
19. Fleischhacker, W. W., C. Barnas, C. H. Stuppäck, B. Unterweger, H. Hinterhuber: Zotepine in the treatment of negative symptoms in chronic schizophrenia. Pharmacopsychiatry 20 (1987) 58-60.
20. Barnas, C., C. H. Stuppäck, B. Unterweger, H. Hinterhuber, W. W. Fleischhacker: Treatment of negative symptoms in schizophrenia with zotepine. J. Clin. Psychopharmacol. 7 (1987) 370-371.
21. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. DSM-III-R, American Psychiatric Association, Washington (DC) 1987.
22. Dieterle, D. M., M. I. Albus, E. Eben, M. Ackenheil, W. Rockstroh: Preliminary experiences and results with the Munich version of the Andreasen scale. Pharmacopsychiatry 19 (1986) 96-100.
23. National Institute of Mental Health: Clinical Global Impressions (CGI). In: Collegium Internationale Psychiatriae Scalarum (ed.) : Internationale Skalen fúr Psychiatrie. Beltz Test GmbH, Weinheim 1981.
24. National Institute of Mental Health: Dosage Record and Treatment Emergent Symptom Scale (DOTES). In: Collegium Internationale Psychiatriae Scalarum (ed.) : Internationale Skalen fúr Psychiatrie. Beltz Test GmbH, Weinheim 1981.
25. Ceulemans, D. L. S., Y. G. Gelders, M. L. Hoppenbrouwers, A. J. M. Reyntijens, P. A. J. Janssen: Effect of serotonin antagonism in schizophrenia: a pilot study with setoperone. Psychopharmacology 85 (1985) 329.
26. Stahl, S. M., K. Wets: Indolamines and schizophrenia. In: Henn, F. A., L E. DeLisi (eds.) : Handbook of Schizophrenia, Vol.2: Neurochemistry and Neuropharmacology of Schizophrenia, Elsevier, Amsterdam 1987, pp. 257-296.
27. Kane, J., G. Honigfeld, J. Singer, H. Meltzer: Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. gen. Psychiat. 45 (1988) 789-796.